Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Israel, Fertile Land for Device Company Creation

This article was originally published in Start Up

Executive Summary

A surprisingly large number of medical device start-ups emerge from Israel, and at the recent In3 (Investment in Innovation) conference sponsored by the Medtech Insight division of Windhover Information Inc. in Brussels, Belgium in late September, a distinguished panel of venture capitalists made sense of the country's unique climate for device innovation. The speakers also had some lessons to offer to fledgling European device companies as well. Taking part in the panel were Avi Molcho, MD, Managing Director, Life Sciences, for Giza Venture Capital, one of Israel's largest venture firms, Zeev Zehavi, VP of Johnson & Johnson Development Corp., responsible for J&J's corporate investments in Europe and Israel, and Yuval Binur, PhD, Chairman of the board of device company creator Accelerated Technologies.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel